Dominican University of California
 

All Conference Presentations, Performances and Exhibits

Presentation or Panel Title

Occupations as an Outcome Measure in a Clinical Trial: Fragile X Syndrome and Sertraline

Location

Guzman 111

Start Date

4-15-2016 1:40 PM

End Date

4-15-2016 1:55 PM

Department

Occupational Therapy

Student Type

Graduate

Faculty Mentor

Laura Greiss Hess, PhD, OTR/L

Presentation Format

Oral Presentation

Abstract/Description

Fragile X Syndrome (FXS) is the most common form of inherited intellectual and developmental disability (IDD) and the most common known genetic cause of autism. Individuals diagnosed with FXS present with deficits in social skills, sensory processing, cognition, behavior, and language development. The purpose of this research is to examine family perspectives collected during baseline and follow-up interviews as part of a randomized, controlled, medication trial of Sertraline (Zoloft) on children two to six years old diagnosed with FXS. Interview data and qualitative analysis will be used to examine family accounts of their child’s improvements in daily life contexts over the course of the clinical trial. Differences in improvements will be compared between the treatment and placebo groups. This qualitative data analysis may prove to be a more sensitive measure in contrast to standardized measurements, which can be limited in their ability to show change over time with IDD populations.

This document is currently not available here.

Share

Import Event to Google Calendar

COinS
 
Apr 15th, 1:40 PM Apr 15th, 1:55 PM

Occupations as an Outcome Measure in a Clinical Trial: Fragile X Syndrome and Sertraline

Guzman 111

Fragile X Syndrome (FXS) is the most common form of inherited intellectual and developmental disability (IDD) and the most common known genetic cause of autism. Individuals diagnosed with FXS present with deficits in social skills, sensory processing, cognition, behavior, and language development. The purpose of this research is to examine family perspectives collected during baseline and follow-up interviews as part of a randomized, controlled, medication trial of Sertraline (Zoloft) on children two to six years old diagnosed with FXS. Interview data and qualitative analysis will be used to examine family accounts of their child’s improvements in daily life contexts over the course of the clinical trial. Differences in improvements will be compared between the treatment and placebo groups. This qualitative data analysis may prove to be a more sensitive measure in contrast to standardized measurements, which can be limited in their ability to show change over time with IDD populations.